IAC Express 2010 |
Issue number 870: June 1, 2010 |
|
Please click here to subscribe to IAC Express
as well as other FREE IAC periodicals. |
|
Contents
of this Issue
Select a title to jump to the article. |
- MMWR
discusses licensure of bivalent human papillomavirus vaccine (HPV2,
Cervarix) for use in females and presents CDC's updated HPV vaccination
recommendations
- MMWR
discusses licensure of quadrivalent human papillomavirus vaccine (HPV4,
Gardasil) for use in males and presents CDC's guidance for its use
- New: CDC
publishes interim VIS for MMRV vaccine
- Check out
IAC's redesigned print materials section
- IAC
develops new handout to help healthcare professionals administer
pneumococcal vaccines to children
- IAC
updates "Do I need any vaccinations today?"
- AAP
releases policy statement on the prevention of Streptococcus pneumoniae
infections in infants and children
- IAC's
Video of the Week offers a personal perspective on chronic hepatitis B
virus infection
- Hep B
Moms helps empower women so they can say, "Hep B stops with me"
- Interim
VIS for pneumococcal conjugate vaccine (PCV13) now available in Indonesian
- CDC's
Epidemiology & Prevention of Vaccine-Preventable Diseases course to be
offered in Colorado, July 12-14
|
|
Abbreviations |
|
AAFP, American Academy of Family Physicians; AAP,
American Academy of Pediatrics; ACIP, Advisory Committee on Immunization
Practices; AMA, American Medical Association; CDC, Centers for Disease
Control and Prevention; FDA, Food and Drug Administration; IAC, Immunization
Action Coalition; MMWR, Morbidity and Mortality Weekly Report; NCIRD,
National Center for Immunization and Respiratory Diseases; NIVS, National
Influenza Vaccine Summit; VIS, Vaccine Information Statement; VPD,
vaccine-preventable disease; WHO, World Health Organization. |
|
Issue 870: June 1, 2010 |
|
|
1. |
MMWR discusses licensure of bivalent human papillomavirus vaccine (HPV2,
Cervarix) for use in females and presents CDC's updated HPV vaccination
recommendations
CDC published "FDA Licensure of Bivalent Human
Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females
and Updated HPV Vaccination Recommendations from the
Advisory Committee on Immunization Practices (ACIP)" in the
May 28 issue of MMWR. The first paragraph and the section
titled Vaccine Recommendations for HPV2 and HPV4 are
reprinted below. For detailed information about the
recommendations, including dosage, administration, and
schedules; special situations; and precautions and
contraindications, see the links to the complete
recommendations given at the end of this IAC Express
article.
On October 16, 2009, the Food and Drug Administration (FDA)
licensed bivalent human papillomavirus vaccine (HPV2;
Cervarix, GlaxoSmithKline) for use in females aged 10
through 25 years. Cervarix is the second human
papillomavirus (HPV) vaccine licensed for use in females in
the United States. Quadrivalent HPV vaccine (HPV4; Gardasil,
Merck & Co, Inc.) was licensed in 2006 for use in females
aged 9 through 26 years, and the Advisory Committee on
Immunization Practices (ACIP) recommended routine HPV4
vaccination of females aged 11 or 12 years, and catch-up
vaccination for females aged 13 through 26 years. This
report provides updated recommendations for routine and
catch-up vaccination of females with either HPV2 or HPV4.
VACCINE RECOMMENDATIONS FOR HPV2 AND HPV4
ACIP recommends routine vaccination of females aged 11 or 12
years with 3 doses of either HPV2 or HPV4. The vaccination
series can be started beginning at age 9 years.
Vaccination is recommended for females aged 13 through 26
years who have not been vaccinated previously or who have
not completed the 3-dose series. If a female reaches age 26
years before the vaccination series is complete, remaining
doses can be administered after age 26 years. Ideally,
vaccine should be administered before potential exposure to
HPV through sexual contact.
ACIP recommends vaccination with HPV2 or HPV4 for prevention
of cervical cancers and precancers. Both vaccines might
provide protection against some other HPV-related cancers in
addition to cervical cancer, although there are currently
only data sufficient to recommend HPV4 for protection
against vulvar and vaginal cancers and precancers. HPV4 is
recommended also for prevention of genital warts.
To access the full article in PDF format, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5920.pdf and see pages 626-629.
To access the article in web-text (HTML) format, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm
Back to top |
|
|
2. |
MMWR discusses licensure of quadrivalent human papillomavirus vaccine (HPV4,
Gardasil) for use in males and presents CDC's guidance for its use
CDC published "FDA Licensure of Quadrivalent
Human
Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and
Guidance from the Advisory Committee on Immunization
Practices (ACIP)" in the May 28 issue of MMWR. The first
paragraph and the section titled Vaccine Guidance are
reprinted below. For detailed information about the
recommendations, including administration, special
situations, and precautions and contraindications, see the
links to the complete recommendations given at the end of
this IAC Express article.
On October 16, 2009, the Food and Drug Administration
licensed quadrivalent human papillomavirus vaccine (HPV4;
Gardasil, Merck & Co. Inc.) for use in males aged 9 through
26 years for prevention of genital warts caused by human
papillomavirus (HPV) types 6 and 11. HPV4 had been licensed
previously for use in females aged 9 through 26 years for
prevention of HPV 6, 11, 16, and 18-related outcomes (i.e.,
vaginal, vulvar, and cervical precancers and cancers and
genital warts). The Advisory Committee on Immunization
Practices (ACIP) recommends routine vaccination of females
at age 11 or 12 years and catch-up vaccination for females
aged 13 through 26 years. On October 21, 2009, ACIP provided
guidance that HPV4 may be given to males aged 9 through 26
years to reduce their likelihood of acquiring genital warts;
ACIP does not recommend HPV4 for routine use among males.
This report presents the ACIP policy statement and
summarizes background data. Issues reviewed by ACIP included
efficacy, immunogenicity, and safety of the HPV4 vaccine in
males, epidemiology of HPV and burden of HPV-associated
diseases and cancers in males, cost-effectiveness of male
vaccination, and programmatic considerations.
VACCINE GUIDANCE
The 3-dose series of HPV4 may be given to males aged 9
through 26 years to reduce their likelihood of acquiring
genital warts. HPV4 would be most effective when given
before exposure to HPV through sexual contact.
To access the full article in PDF format, go to:
http://www.cdc.gov/mmwr/PDF/wk/mm5920.pdf and see pages 630-631.
To access the article in web-text (HTML) format, go to:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm
Back to top |
|
|
3. |
New: CDC publishes interim VIS for MMRV vaccine
On May 21, CDC published a new interim VIS
specifically for
measles, mumps, rubella, and varicella (MMRV) vaccine. This
VIS is the preferred VIS for children getting MMRV vaccine,
as it contains more detailed information about the risk of
febrile seizures.
To access the 5/21/10 interim VIS for MMRV vaccine from the
IAC website, go to: http://www.immunize.org/vis/mmrv.pdf
For information about the use of VISs, and for VISs in more
than 35 languages, visit IAC's VIS web section at
http://www.immunize.org/vis
For general information about VISs from CDC's website go to:
http://www.cdc.gov/vaccines/pubs/vis
For CDC's latest news on VISs, go to
http://www.cdc.gov/vaccines/pubs/vis/vis-news.htm
Back to top |
|
|
4. |
Check out IAC's redesigned print materials section
IAC's "Print Materials" web section has been
renamed
"Handouts for Patients and Staff" and totally redesigned to
better serve users. To enter it, go to:
http://www.immunize.org/handouts
The first thing you'll see is the organizing heart of the
page, a large central box with tabs labeled Clinic
Procedures, Vaccine Index, Topic Index, and Language Index
running horizontally across it.
The Clinic Procedures index provides links to handouts
organized by such categories as Administering Vaccines,
Documenting Vaccination, Handling and Storage, and Medical
Management (total of 11 categories).
Click on the Vaccine Index to be taken to links providing
access to the handouts organized by vaccine (e.g., HPV,
meningococcal, or pertussis; total of 20 vaccines).
The Topic Index provides links to handouts by such topics as
Laws & Mandates, Dialysis, and Healthcare Personnel (total
of 12 topics).
Click on the Language Index, and you'll be offered links to
the 12 languages for which IAC offers handouts in
translation.
Go into any of the subsections of any index, and run your
mouse over the titles of the listed handouts and watch a
preview of the piece pop up in the column on the right.
Finally, another useful feature of the "Handouts for
Patients and Staff" web section is a link titled View All
Handouts located at the bottom left edge of the central box.
Click the link to be taken to sortable table that allows
visitors, using up/down arrows, to sort the handouts
alphabetically by title, and also by language, date, and
item number.
Spend some time exploring IAC's new state-of-the-art
"Handouts for Patients and Staff" web section and be sure to
bookmark http://www.immunize.org/handouts for easy reference
in the future.
Back to top |
|
|
5. |
IAC develops new handout to help healthcare professionals administer
pneumococcal vaccines to children
Many healthcare providers have questions about
the use of
the new 13-valent pneumococcal conjugate vaccine (PCV13),
especially when dealing with catch-up vaccination and
children with medical conditions that are indications for
both PCV and pneumococcal polysaccharide vaccine (PPSV23).
To help answer such questions, IAC has developed a new
handout, "Recommendations for Pneumococcal Vaccine Use in
Children," that spells out the recommendations for every
scenario.
This new resource includes three tables. The first table
provides the recommended PCV13 schedule based on the child's
age and PCV7 and/or PCV13 vaccination history. The second
table provides the recommended schedule for administering
PPSV23 vaccine to children; the third table lists the
underlying medical conditions that are indications for
pneumococcal vaccination among children.
To access the ready-to-print (PDF) handout "Recommendations
for Pneumococcal Vaccine Use in Children," go to:
http://www.immunize.org/catg.d/p2016.pdf
IAC's Handouts for Patients and Staff web section offers
healthcare professionals and the public approximately 250
FREE English-language handouts (many also available in
translation), which we encourage website users to print out,
copy, and distribute widely. To access all of IAC's free
handouts, go to: http://www.immunize.org/handouts
Back to top |
|
|
6. |
IAC updates "Do I need any vaccinations today?"
IAC recently revised the handout titled "Do I
need any
vaccinations today?" This resource is a screening tool for
patients to fill out before seeing their healthcare
provider. The handout was updated to include new
recommendations related to influenza.
To access the revised ready-to-print (PDF) handout "Do I
need any vaccinations today?" go to:
http://www.immunize.org/catg.d/p4036.pdf
IAC's Handouts for Patients and Staff web section offers
healthcare professionals and the public approximately 250
FREE English-language handouts (many also available in
translation), which we encourage website users to print out,
copy, and distribute widely. To access all of IAC's free
handouts, go to: http://www.immunize.org/handouts
Back to top |
|
|
7. |
AAP releases policy statement on the prevention of Streptococcus pneumoniae
infections in infants and children
On May 24, the American Academy of Pediatrics (AAP)
posted
the new policy statement "Recommendations for the Prevention
of Streptococcus pneumoniae Infections in Infants and
Children: Use of 13-Valent Pneumococcal Conjugate Vaccine
(PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23)."
To access it, go to:
http://aapredbook.aappublications.org/implementation/pedsPCV13052410.pdf
IAC keeps an up-to-date, sortable list of all AAP policy
statements related to immunization at http://www.immunize.org/aap
Back to top |
|
|
8. |
IAC's Video of the Week offers a personal perspective on chronic hepatitis B
virus infection
IAC encourages IAC Express readers to watch a
2.5-minute
video on perinatal hepatitis B infection, produced by PKIDs
(Parents of Kids with Infectious Diseases). In this moving
video, a mother shares her feelings about her daughter's
chronic hepatitis B virus (HBV) infection.
Chronic infection is much more likely to develop in those
who are infected in the first year of life. Approximately 90
percent of children who are infected during the first year
of life will become chronically infected. Most of these
infants could have been protected from HBV infection by
proper prophylaxis (hepatitis B vaccine and hepatitis B
immunoglobulin [HBIG]) at birth. About 1 out of 4 infected
babies will die of liver failure or liver cancer as adults.
Audio and video public service announcements (PSAs) based on
the 2.5-minute video are available in different formats and
in 30- and 60-second lengths for use by organizations free
of charge.
The link to the PKIDs web page featuring the video will be
available on the home page of IAC's website through June 6.
To access it, go to: http://www.immunize.org and click on
the image under the words Video of the Week.
Remember to bookmark IAC's home page to view a new video
every Monday. To view an IAC Video of the Week from the
past, go to the video archive at http://www.immunize.org/votw
Back to top |
|
|
9. |
Hep
B Moms helps empower women so they can say, "Hep B stops with me"
Hep B Moms is a non-profit
organization dedicated to
preventing mother-to-child transmission of hepatitis B and
safeguarding the health of infected mothers and their
families.
Many pregnant mothers with chronic hepatitis B are unaware
of their infection, which they may have acquired from their
own mothers at birth. Like their mothers, pregnant women
with chronic hepatitis B sometimes end up silently passing
the virus onto the next generation.
The slogan "Hep B stops with me" is the catchphrase Hep B
Moms uses to state its determination to empower women with
the information they need to safeguard their own health if
they are infected, and to ensure that their children neither
acquire hepatitis B infection nor pass it on to another
generation.
As part of its goal to prevent mother-to-child transmission
of hepatitis B, Hep B Moms advocates for (1) hepatitis B
vaccination for newborns at birth (as well as hepatitis B
immunoglobulin [HBIG] administration for infants born to
infected mothers) and (2) complete vaccination with the
hepatitis B vaccine series.
As part of its current activities, Hep B Moms asks that moms
pledge to do at least one of the following:
-
Vaccinate their child against hepatitis B
-
Tell a friend about hepatitis B
-
Learn more about hepatitis B and liver cancer
-
Blog about Hep B Moms
The pledge is part of the "Hep B Stops with Me" contest that
Hep B Moms is sponsoring between now and June 30. The
mother's written pledge, along with a photo of her child,
forms a collage that promotes hepatitis B vaccination among
a community of women who choose to make a difference. To
view the collage, go to: http://hepbmoms.org/New_moms.php
To find out more about the contest, go to:
http://hepbmoms.org/New_moms2.php
Hep B Moms works with physicians, public health officials,
and the general public to improve hepatitis B knowledge and
awareness. To find out more about the organization's broad
range of activities, go to: http://www.hepbmoms.org.
Back to top |
|
|
10. |
Interim VIS for pneumococcal conjugate vaccine (PCV13) now available in
Indonesian
Dated 4/16/10, the interim VIS for 13-valent
pneumococcal
conjugate vaccine (PCV13) is now available in Indonesian.
IAC gratefully acknowledges DT Interpreting and Wentworth
Douglass Hospital, Dover, NH, for the translation.
To access the new translation of the interim VIS for PCV13,
as well as this VIS in English and other languages, go to:
http://www.immunize.org/vis/vis_pcv.asp
For information about the use of VISs, and for VISs in more
than 35 languages, visit IAC's VIS web section at
http://www.immunize.org/vis
Back to top |
|
|
11. |
CDC's Epidemiology & Prevention of Vaccine-Preventable Diseases course to be
offered in Colorado, July 12-14
CDC's popular Epidemiology & Prevention of
Vaccine-Preventable Diseases course will be offered in Estes Park,
CO, July 12-14. For more information, go to:
http://www.cdc.gov/vaccines/ed/downloads/co-brochure2010.pdf
Back to top |
|
|
|